LCT to benefit from Semma Therapeutics acquisition by Vertex
AUCKLAND: Living Cells Technologies (LCT) holds 121,995 shares in Semma Therapeutics, worth an anticipated USD 838,105 which would be realised on Vertex Pharmaceuticals Incorporated completing its acquisition of Semma Therapeutics. The acquisition is anticipated to close in the fourth quarter…